A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

British Journal of Clinical Pharmacology

Volumn 63, Issue 4, 2007, Pages 421-430

  Jakubowski, Joseph A ^a   Matsushima, Nobuko ^b   Asai, Fumitoshi ^b   Naganuma, Hideo ^b   Brandt, John T ^a   Hirota, Takashi ^b   Freestone, Stephen ^c   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c Inveresk Clinical Research Limited   (United Kingdom)

Author keywords

ADP; Clopidogrel; P2Y12; Platelet aggregation inhibitors; Prasugrel; Thienopyridine

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; DRUG METABOLITE; PLACEBO; PRASUGREL; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; R 100932; R 106583; R 95913; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEMATOLOGY; HUMAN; MALE; METHODOLOGY; MULTIPLE DRUG DOSE; NORMAL HUMAN; OCCULT BLOOD; OPHTHALMOSCOPY; PETECHIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; URINALYSIS; VITAL SIGN;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THIOPHENES; TICLOPIDINE;

EID: 33947284488     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02792.x     Document Type: Article

References (31)

1. Badimon L, Badimon JJ, Fuster V. Pathophysiology of arterial thrombosis. In Platelets in thrombotic and non thrombotic disorders, 1st edn, eds Gresele, P, Page, C, Fuster, V, Vermylen, J. New York: Cambridge University Press, 2002, 727-37.
2. Goldschmidt PJ, Lopes N, Crawford LE. Atherosclerosis and coronary artery disease. In Platelets, 1st edn, ed. Michelson, AD. San Diego: Elsevier Science USA, 2002, 375-98.
3. 1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-4.
4. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-8.
5. 12 receptor in platelet activation. J Clin Invest 2004; 113: 340-5.
6. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
7. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W, Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
8. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Shaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). http://www.acc.org/clinicalguidelines/unstable/ unstable.pdf.2002. Accessed on May 11, 2005.
9. Boersma E, Harrington RA, Moliterno DJ, White H, Van de Theroux PWF, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.
10. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
11. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
12. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
14. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
15. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-8.
16. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003; 91: 1123-5.
17. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
18. Muller I, Besta F, Schulz C, Massberg S, Schomig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
19. Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, Koike H. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G (i) -linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132: 47-54.
20. 12 inhibitor. A single ascending dose study healthy humans. Platelets 2006; 17: 209-17.
21. 12 Inhibitor: a multiple dose study in healthy humans. Platelets 2006; 17: 218-26.
22. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129: 1439-46.
23. 12 receptor antagonist activity. Sem Thromb Hemost 2005; 31: 184-94.
24. Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985; 60: 635-42.
25. Ivy AC, Nelson D, Bercher G. The standardization of certain factors in the cutaneous venostasis bleeding time technique. J Lab Clin Med 1941; 26: 1812-22.
26. Wong E, McIntosh M, Garofolo F, Shwajch A, Kennedy M, Young M, Cameron C, Pang H, Kawabata K, Takahashi M. Bioanalytical assay for LY640315 (CS-747) three inactive metabolites in human plasma by LC-MS/MS. J Am Soc Mass Spectrom 2004; 15: 23S.
27. Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Sem Thromb Hemost 1999; 25(Suppl 2): 9-14.
28. Cahill RA, McGreal GT, Crowe BH, Ryan DA, Manning BJ, Cahill MR, Redmond HP. Duration of increased bleeding tendency after cessation of aspirin therapy. J Am Coll Surg 2005; 200: 564-73.
29. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
30. 12 antagonist, to clopidogrel in percutaneous coronary intervention; Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) -TIMI 26 Trial. Circulation 2005; 111: 3366-73.
31. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-73.